XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: An update meta-analysis based on 4708 subjects

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 1, 2015, Pages 145-154

  Gu, Ai Qin ^a   Wang, Wei Ming ^a   Chen, Wen Yi ^a   Shi, Chun Lei ^a   Lu, Jian Hong ^a   Han, Jun Qing ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Meta analysis; Non small cell lung cancer; Platinum based drug; Single nucleotide polymorphism; XRCC1

Indexed keywords

PLATINUM DERIVATIVE;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER CHEMOTHERAPY; CAUCASUS POPULATION; CHINESE; CLINICAL TRIAL (TOPIC); DATA PROCESSING; DRUG SENSITIVITY; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PUBLISHING; QUALITY CONTROL; RELIABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; XRCC1 GENE;

EID: 84923000796     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hancock J, Rosen J, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Management of clinical stage IIIA primary lung cancers in the National Cancer Database. Ann Thorac Surg 2014; 98: 424-32.
2. Szasz A. Current status of oncothermia therapy for lung cancer. Korean J Thorac Cardiovasc Surg 2014; 47: 77-93.
3. Yamaguchi M, Sugio K. Current status of induction treatment for N2-Stage III non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2014; 62: 651-9.
4. Lee SY, Kang HG, Yoo SS, Kang YR, Choi YY, Lee WK, Choi JE, Jeon HS, Shin KM, Oh IJ, Kim KS, Lee J, Cha SI, Kim CH, Kim YC, Park JY. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer 2013; 82: 330-9.
5. Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res 2014; 13: 7617-25.
6. Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y, Wang D. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer 2014; 135: 2687-96.
7. Zhang L, Ma W, Li Y, Wu J, Shi GY. Phar-macogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Ge-net Mol Res 2014; 13: 228-36.
8. Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, Shu Y, Shao Y, Yin Y. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2013; 71: 1287-95.
9. Chen J, Zhao QW, Shi GM, Wang LR. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B 2012; 13: 875-83.
10. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q, Wang JC. Predictive value of XRCC1 gene polymorph-isms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 2012; 18: 3972-81.
11. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O’Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002; 156: 300-10.
12. Xu C, Wang X, Zhang Y, Li L. Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2011; 14: 912-7.
13. Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly 2011; 141: w13275.
14. Li D, Zhou Q, Liu Y, Yang Y, Li Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol 2012; 29: 1622-8.
15. Dong J, Hu Z, Shu Y, Pan S, Chen W, Wang Y, Hu L, Jiang Y, Dai J, Ma H, Jin G, Shen H. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. Mol Carcinog 2012; 51: 546-52.
16. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 118-23.
17. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z. Polymorphisms in XR-CC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65: 230-6.
18. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007; 13: 2876-81.
19. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Zhang XR, Xu BH, Lin DX. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhong-hua Zhong Liu Za Zhi 2006; 28: 196-9.
20. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-601.
21. Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, Baiget M, Barnadas A. Phar-macogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 2014; 353: 160-6.
22. Song D, Liu J, Wang Z, Song B, Li C. Single nucleotide polymorphisms in XRCC1 and XPD and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Chin J Gerontol 2007; 27: 1684-6.
23. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Mas-suti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R; Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine- treated non-small-cell lung cancer patients. Ann Oncol 2006; 17: 668-75.
24. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jia-zhong J, Yingfeng Z. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65: 230-6.
25. Gao C, Shi M, Wu J, Cao H, Feng J, Xu L. Poly-morphisms in XRCC1 gene and sensitivity to gemcitabine/cisplatin chemotherapy in non-small cell lung cancer. Pract J Cancer 2006; 21: 351-3.
26. Qian X, Qiu L, Yang Y, Jiang M, Zhang Y, Yu L, et al. Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. J Modern Oncol 2010; 18: 1303-5.
27. Wang Z, Miao X, Tan W, Zhang X, Xu B, Lin D. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Chin J Cancer 2004; 23: 865-8.
28. Cheng HY, Chen BA, Sun XC, Sun N, Cheng HY, Li F, Zhang HM, Feng JF, Qin SK, Cheng L, Lu ZH. Relationship of single nucleotide polymorphisms and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Jiang Su Med J 2011; 37: 272-274.
29. Ding CL, Liu LH and Song H. Polymorphism in XRCC1 and sensitivity to platin-based chemotherapy in advanced non-small cell lung cancer. China Pharm 2010; 13: 1399-1401.
30. Hong CY, Xu Q, Yue Z, Zhang Y, Yuan Y. Corre-lation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. Ai Zheng 2009; 28: 1291-1297.
31. Jin YW, Liu J and Wang ZH. Prediction of XPD and XRCC1 gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Shandong Yi Yao 2006; 46: 42-43.
32. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q, Wang JC. Predictive value of XRCC1 polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Mod Oncol 2009; 17: 263-265.
33. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 2012; 7: 973-81.
34. Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res 2014; 13: 7617-25.
35. Liu D, Wu J, Shi GY, Zhou HF, Yu Y. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. Genet Mol Res 2014; 13: 3100-7.
36. Han Y, Lv HY, Yao RY. Effects of polymorphisms in the XRCC1, ERCC1 genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Zhongguo Shi Yong Nei Ke Za Zhi 2011; 31: 638-639.
37. Zhao W, Hu LM, Wang Q. Effects of polymorphisms in the XRCC1, PARP1, and APE1 genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Journal of Nanjing Medical University 2011; 31: 638-639.
38. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Sco-ttish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25: 4528-35.
39. Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphi-sms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 2008; 111: 509-15.